Skip to: Content
Skip to: Site Navigation
Skip to: Search

July 24, 2008 8:10:39 AM CDT

Learn about Newser Points »

« Back to the grid | Next story »

Diabetes Drug Ups Heart Risk

Posted May 21, 07 3:15 PM CDT in Science & Health 

(Newser) – A popular diabetes drug may increase heart attack risks, a study reported in the New England Journal of Medicine concludes. Patients who took Avandia, which treats Type 2 diabetes, were 43% more likely to have a heart attack than those who took a placebo, the Cleveland Clinic study found.

GlaxoSmithKline says the findings are not definitive, and the company will not pull the drug, prescribed to 2 million people each year, from the market. Nor will the FDA step in at this point, the agency says. But the New York Times reports that the company's own trial showed a 66% increase in heart attacks in patients taking Avandia, and a 20% spike in their risk of death from cardiovascular problems.

Source Associated Press

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon

Related Newser Stories

  • Diabetes Drug Given Strictest Warning Label

    Nov 14, 07 3:20 PM CST
    Diabetes Drug Given Strictest Warning Label The FDA has applied its harshest warning to the diabetes drug Avandia, declaring the product potentially increases risk of heart attacks. Now marked with a “black box” warning, GlaxoSmithKline’s drug will stay on the market pending a continuing “safety assessment,” the Wall Street Journal reports; FDA officials say the agency remains split on the wisdom of pulling the drug immediately. More »

  • Generics Curb Rise in Drug Costs

    Aug 8, 07 6:37 PM CDT
    Generics Curb Rise in Drug Costs Scores of prescription drugs are getting cheaper, as name-brand patents expire and open the door to generic imitators. That's bad news for pharmaceutical companies, the Times reports, but it means that an aging population ever more reliant on drugs will be paying as much as 80 percent less for them. More »

  • FDA Panel Votes to Keep Avandia on Shelves

    Jul 30, 07 5:38 PM CDT
    FDA Panel Votes to Keep Avandia on Shelves An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs. More »

  • Controversy Rages Over Diabetes Drug's Heart Risks

    Jun 6, 07 12:16 PM CDT
    Controversy Rages Over Diabetes Drug's Heart Risks Troubling questions about the diabetes drug Avandia persisted yesterday as an FDA official revealed that she was barred from recommending a critical warning about the medication, the Times reports. In the run-up to congressional hearings that began today, manufacturer GlaxoSmithKline rushed to disseminate interim clinical findings in hopes of blunting the controversy. More »

  • Glaxo Stems Stock Slide Over Avandia

    May 31, 07 6:44 AM CDT
    Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks.  A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence of heart attacks among Avandia patients—0.6%—was still very small. More »

The company logo of GlaxoSmithKline, is seen on the headquarters building in London, in this May 10, 2006 file photo. GlaxoSmithKline PLC is expected to release quarterly earnings on Wednesday, April...   (Associated Press)
  (IndexOpen (http://www.indexopen.com))
« Prev« Prev | Next »Next » Slideshow
Our editors also recommend:

Threads (1 of 4)

Tags

health  • medicine  • FDA  • medical research  • diabetes  • heart attack  • pharmaceutical companies  • GlaxoSmithKline  • Avandia  • pharma


Loading...

Loading...

Today's Most Popular


Other Home Stories

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »